PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

20170730 175154
DJI 0014
20180816 195949
DJI 0017
IMG-20170805-WA0001
DJI 0072
  • Untitled Letters
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-16 By FDA
  • Reviews of Pediatric Studies Conducted under BPCA and Pediatric assessments conducted under PREA from 2012 – present
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-15 By FDA
  • Ongoing | Cancer Accelerated Approvals
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-15 By FDA
  • VYJUVEK
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-09-15 By FDA
  • Human medicines European public assessment report (EPAR): Baqsimi, glucagon, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-15
  • Generic Drug User Fee Amendments
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-15 By FDA
  • GDUFA Paid Facilities List
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-15 By FDA
  • FDA Online Controlled Substances Summit, Washington, D.C. - 09/11/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-15 By FDA
  • Human medicines European public assessment report (EPAR): Emselex, darifenacin hydrobromide, Date of authorisation: 22/10/2004, Revision: 28, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-15
  • Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 22, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-15
  • Human medicines European public assessment report (EPAR): Thalidomide Lipomed, thalidomide, Date of authorisation: 19/09/2022, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-15
  • Human medicines European public assessment report (EPAR): Locametz, gozetotide, Date of authorisation: 09/12/2022, Revision: 7, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-15
  • Advancing Generic Drug Development: Translating Science to Approval 2025 - 10/07/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-15 By FDA
  • Influenza (Flu) Antiviral Drugs and Related Information
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
  • Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
Older posts
Theme: Scaffold by Danny Cooper.